ClinicalTrials.gg

Program

aramchol

Its studies are mostly in Fatty Liver · Gallstones · Non-alcoholic Fatty Liver Disease · Hypercholesterolemia, led by 3 companies.

Furthest: phase 2, since Nov 12, 201410 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Galmed Pharmaceuticals71 open or runningphase 2since Nov 12, 2014Nov 12, 2014none ahead
Galmed Medical Reserch20 open or runningphase 2since Feb 17, 2010Oct 19, 2008none ahead
Galmed Research and Development10 open or runningphase 2since Oct 23, 2014Oct 23, 2014none ahead

Also a collaborator on its studies: quotient-sciences, sharp, clinintel, itamar-medical-israel, one-way-liver-owl, transperfect, clinical-reference-laboratory, alderley-analytical-ltd and wcct-global.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 19, 2008First study: phase 1 study in HypercholesterolemiaNew to Galmed Medical ReserchGalmed Medical Reserch · NCT00776841 · 41 enrolled · Israel
  2. Feb 17, 2010Phase 2 study in Non-alcoholic Fatty Liver DiseaseGalmed Medical Reserch · NCT01094158 · 60 enrolled · Israel
  3. Oct 23, 2014Galmed Research and Development's first study: phase 2 study in Fatty LiverNew to Galmed Research and DevelopmentGalmed Research and Development · NCT02279524 · 247 enrolled · United States, Chile, France and more
  4. Nov 12, 2014Galmed Pharmaceuticals's first study: phase 2 study in GallstonesNew to Galmed PharmaceuticalsGalmed Pharmaceuticals · NCT02325492 · 10 enrolled · Israel
  5. Jan 18, 2015Phase 1 study in Healthy VolunteersGalmed Pharmaceuticals · NCT02374437 · 66 enrolled
  6. Jun 7, 2016Phase 1 study in Healthy VolunteersGalmed Pharmaceuticals · NCT02803996 · 64 enrolled · United States
  7. Nov 22, 20182 phase 1 studies in HealthyGalmed Pharmaceuticals · NCT03760848, NCT03774173
  8. Apr 24, 2023Phase 1 study in NASHGalmed Pharmaceuticals · NCT05874336 · 6 enrolled · United Kingdom
  9. Nov 14, 2025Phase 1 study in HealthyGalmed Pharmaceuticals · NCT07251712 · 32 planned · United Kingdom

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 10 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07251712Healthy · United Kingdom1RecruitingGalmed PharmaceuticalsApr 15, 202632
NCT05874336NASH · United Kingdom1CompletedGalmed PharmaceuticalsAug 11, 20206
NCT03774173Healthy · United Kingdom1CompletedGalmed PharmaceuticalsFeb 3, 201916
NCT03760848Healthy · United Kingdom1CompletedGalmed PharmaceuticalsFeb 2, 201915
NCT02803996Healthy Volunteers · United States1CompletedGalmed PharmaceuticalsSep 201664
NCT02374437Healthy Volunteers1CompletedGalmed PharmaceuticalsDec 201466
NCT02325492Gallstones · Israel2TerminatedGalmed PharmaceuticalsOct 201510
NCT02279524Fatty Liver · United States, Chile, France and more2CompletedGalmed Research and DevelopmentMay 22, 2018247
NCT01094158Non-alcoholic Fatty Liver Disease · Israel2CompletedGalmed Medical ReserchNov 201160
NCT00776841Hypercholesterolemia · Israel1CompletedGalmed Medical ReserchSep 200941

How it is read

Names in the registry

  • “Aramchol”, 13 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.